Key facts
- This page summarizes Eiry Roberts's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Dec 2024, 16:47.
Eiry Roberts - 17 Dec 2024 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- NBIX
- Reported as of
- 17 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Dec 2024, 16:47:06 UTC
- Prior SEC filing
- 12 Nov 2024
- Next SEC filing
- 04 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darin Lippoldt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eiry Roberts filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 19 Dec 2024.
Change
- Previous filing in this sequence was filed on 12 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBIX
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +5,487
- Change %
- Price
- $0.000000
- Shares after
- 5,487
- Date
- 17 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,487
- Exercise price
- Footnotes
- F1, F2
NBIX
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +27,770
- Change %
- Price
- $0.000000
- Shares after
- 27,770
- Date
- 17 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,770
- Exercise price
- $136.69
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
Footnote F2
The Restricted Stock Units will vest 1/4 of the units on February 13, 2025, and then annually 1/4 of the shares will vest on February 13, 2026, February 13, 2027, and February 13, 2028.
Footnote F3
Represents an option of which 1/4 of the shares underlying the option becomes vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.